CytoReason, a biotechnology company leveraging computational disease models to help biopharma companies make informed decisions through a data-driven approach, has raised $80 million in a series C funding round to scale its AI-powered disease models.
According to the company’s announcement, the new funding will also accelerate growth, grow clinical and molecular data, expand the application of innovative models, strengthen its market position, and establish its hub in Cambridge, Massachusetts.
Co-founded in 2016 by David Harel and Shai Shen-Orr, CytoReason has received significant support from diverse investors, propping its total amount raised and market valuation. In the recently concluded Series C funding round, the company received substantial investments from OurCrowd, Pfizer, NVIDIA, and Thermo Fisher Scientific.
CytoReason AI Disease Models Platform
CytoReason’s platform is designed to help therapeutic leaders, scientists, and research teams make well-informed decisions using valuable AI tools and molecular-level insights based on available data. This reduces R&D timelines, helps improve the probability of technical and regulatory success (PTRS), and builds an optimized R&D portfolio.
Currently, CytoReason’s technology is used by six leading pharmaceutical companies globally to make data-backed decisions in immuno-oncology, immunology, metabolism, inflammation, and other sectors.
The company’s scientific innovations regularly appear in top-caliber journals such as Nature, Gut, and Cell.